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p.pozzilli@unicampus.itAbstractObjective: Body weight-related insulin resistance probably plays a role in progression to type 1 diabetes, but has an uncertain
impact following diagnosis. In this study, we investigated whether BMI measured at diagnosis was an independent predictor
of C-peptide decline 1-year post-diagnosis.
Design: Multicentre longitudinal study carried out at diagnosis and up to 1-year follow-up.
Methods: Data on C-peptide were collected from seven diabetes centres in Europe. Patients were grouped according to age
at diagnosis (!5 years, nZ126; O5 years!10 years, nZ295; O10 years !18 years, nZ421; O18 years, nZ410). Linear
regression was used to investigate whether BMI was an independent predictor of change in fasting C-peptide over 1 year.
Models were additionally adjusted for baseline insulin dose and HbA1c.
Results: In individuals diagnosed between 0 and 5 years, 5 and 10 years and those diagnosed O18 years, we found no
association between BMI and C-peptide decline. In patients aged 10–18 years, higher BMI at baseline was associated with a
greater decline in fasting C-peptide over 1 year with a decrease (b 95% CI; P value) of 0.025 (0.010, 0.041) nM/kg per m2
higher baseline BMI (PZ0.001). This association remained significant after adjusting for gender and differences in HbA1c and
insulin dose (bZ0.026, 95% CIZ0.0097, 0.042; PZ0.002).
Conclusions: These observations indicate that increased body weight and increased insulin demand are associated with more
rapid disease progression after diagnosis of type 1 diabetes in an age group 10–18 years. This should be considered in studies
of b-cell function in type 1 diabetes.European Journal of
Endocrinology
(2015) 172, 107–113
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172 :2 108IntroductionType 1 diabetes is considered an autoimmune disorder
caused by inflammatory b-cell destruction, and presenting
in childhood is characterised by loss of weight, ketoaci-
dosis, acute onset and insulin dependency. In contrast,
type 2 diabetes is considered a metabolic disorder usually
presenting in adults, associated with obesity and insulin
resistance (1).
However, insulin resistance may influence disease
progression following diagnosis also in type 1 diabetes.
Yki-Jarvinen & Koivisto (2) showed that newly diagnosed
type 1 diabetes patients who went into remission of
insulin therapy had greater insulin sensitivity than
patients who continued to require insulin therapy. In
addition, they found that more than a year post-diagnosis,
insulin sensitivity in these patients was associated with
body weight and was significantly reduced (2). Ludvigsson
et al. (3) described in a national cohort of patients with
type 1 diabetes that those with higher BMI had higher
C-peptide at diagnosis, but then lost relatively more
C-peptide during the first years after diagnosis.
The concept that insulin resistance may play a key role
in the aetiology of type 1 diabetes is described by the
accelerator hypothesis (4) and by the wider b-cell stress
hypothesis (5).
The accelerator hypothesis argues that type 1 and
type 2 diabetes are disorders that are aggravated by
increased insulin resistance due to body weight gain, set
against different genetic backgrounds, with the autoim-
munity of type 1 diabetes being an expected response to
upregulated b-cell response in individuals with genetic
predisposition to heightened immunoreactivity.
Support for this hypothesis comes from a number of
sources. In addition to the increase in incidence of type 2
diabetes that has paralleled increase in obesity, there has
been an equally striking rise in the incidence of type 1
diabetes (6). Rapid weight gain during the first years of
life has been found to increase the incidence of type 1
diabetes (7) and a number of studies have also shown a
positive correlation between the year of onset of type 1
diabetes and BMI (8, 9, 10). More recently, we have shown
that the decline in fasting C-peptide is more rapid in those
patients with an earlier age of onset of type 1 diabetes, and
that the factors influencing the decline in fasting
C-peptide following diagnosis differ substantially accor-
ding to the age of onset (11). Several studies have reported
data showing that the age of onset of type 1 diabetes is
inversely related with BMI, with children diagnosed at
younger ages typically being heavier than those diagnosedwww.eje-online.orglater (9, 12, 13, 14). Genetic studies have demonstrated
that the proportion of high-risk HLA haplotypes has
declined over time and been replaced by protective
HLA haplotypes, arguing that the environmental contri-
bution to disease risk (i.e. insulin resistance associated
with increased obesity) has become more prominent in
type 1 diabetes aetiology alongside the secular trends
in obesity (15, 16). Finally, several studies indicate that in
individuals at risk for the development of type 1 diabetes,
insulin resistance is an independent risk factor for
disease development (17, 18, 19, 20), and in studies of
identical twins the co-twin who goes on to develop type 1
diabetes is more insulin resistant than the twin who does
not (21). However it is important to add that other
studies question these findings, and hence the theory is
controversial (22).
Although some of the evidence summarised above
suggests a potential key role for insulin resistance in type 1
diabetes aetiology, there has been no direct demonstration
that insulin resistance in type 1 diabetes is detrimental to
b-cell function even though, as mentioned above, it has
been shown that C-peptide decline is more rapid in type 1
diabetic patients with higher BMI (3).
In order to investigate whether body weight influ-
ences loss of C-peptide in type 1 diabetes, we have
investigated the association between BMI measured at
age of onset and change in fasting C-peptide levels in the
first year post-diagnosis using longitudinal data from a
large data set of European type 1 diabetes patients
recruited from seven different centres.Subjects and methods
Subjects
From a cohort of 3929 Caucasian patients with type 1
diabetes of seven European registries (Belgian Diabetes
Registry, Leuven Database, Hungary Database, Spain
Database, Sweden Database, Germany Database, Italy
Database IMDIAB), we included 1252 patients for whom
data on fasting C-peptide, BMI, HbA1c levels and insulin
dose at baseline and additionally for fasting C-peptide at
1 year follow-up were available. Eighty-one patients were
placebo-treated subjects from immune intervention
trails. In each study centre, type 1 diabetes was
diagnosed according to ADA and WHO criteria. A
detailed description of the cohort has been published
elsewhere (11).
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172 :2 109Measurements
Fasting, stimulated C-peptide and HbA1c were measured
by standardised assays at each centre after an overnight
pause in long-acting insulin; fasting glucose was required
to be 70–200 mg/dl at the time of sampling. Baseline
C-peptide was measured within the first 12 weeks since
initiation of insulin therapy. Different methods were used
for C-peptide determination, but all had similar detection
limit (0.01 nM), and each centre covered patients of
different age groups. Weight and height were measured
using standardised procedures and used to calculate BMI
(weight/height2).Statistical methods
Statistical analysis was performed with Stata 11.2
(StataCorp. 2009, Stata Statistical Software: Release 11.2,
TX, USA). Participants were stratified into four groups
according to their age at onset of type 1 diabetes: very
young (%5 years), pre-pubertal (O5 and %10 years),
pubertal (O10 and %18 years) and adult (18–65 years),
and all analyses were performed for the whole study
population and for each group.
To investigate the influence of BMI on change in
fasting C-peptide over 1 year (D C-peptide0–1), linear
regression models were used with change in fasting
C-peptide (C-peptideYear-1KC-peptidebaseline) as an out-
come variable and baseline BMI as the independent
variable of interest. The models were adjusted for change
in BMI over 1 year (D BMIK1) for subjects with available
data about BMI after 1 year from the diagnosis (nZ780).
The models were further adjusted for age of onset, sex,
baseline HbA1c and baseline insulin dose to investigate
whether differences in these variables explained any
observed association between BMI and D C-peptide0–1.
D C-peptide0–1 was included in models as an untrans-
formed variable since data were normally distributed. All
models were also further adjusted for study centre to
account for potential differences in the method
of measurement of C-peptide and HbA1c.
In addition to analysing data using untransformed
BMI variables, for children in the 0–5, 5–10 and 10–18 year
age groups, we also performed regression analysis with
BMI transformed to z-scores by the least mean squares
(LMS) method (23) using the 1990 British Growth
reference (zanthro command in Stata), which accounts
for the fact that differences in BMI between children of
different ages can be a result of differences in growth and
development rather than solely adiposity. However, sincethe use of untransformed BMI or BMI z-scores did not alter
our results, data are reported for untransformed BMI
variables given the ease of interpretation and comparison
with results in adults. Finally, potential interactions
between baseline variables were investigated by fitting
continuous interactions terms in regression models.
To maximise the sample size, we report analyses that
are not restricted to those with non-missing values for all
parameters of interest (BMI, gender, HbA1c and insulin
dose), and hence the sample size for each regression model
is slightly different. However, the results were not different
when we performed sensitivity analysis focusing solely
on individuals with non-missing values for all traits.Results
Baseline characteristics of study participants according to
age of onset are given in Table 1.Association of BMI with change in fasting C-peptide
over 1 year (D C-peptide0–1) in the total cohort
At baseline, individuals with a higher BMI had higher
fasting C-peptide levels with a 5.2% (4.0, 6.5) increase per
1 kg/m2 higher BMI (PZ3.3!10K16).
Individuals with a higher BMI at baseline had a greater
decline in D C-peptide0–1 with each 1 kg/m
2 higher BMI
associated with a decrease (b 95% CI; P value) of K0.012
(K0.020, K0.0046; 0.0002) nM in fasting C-peptide. This
association remained significant after taking into account
the differences in baseline HbA1c levels (PZ0.012) and D
BMI0-1 (PZ0.026), but not when variation in baseline
insulin dose (PZ0.060) or both HbA1c levels and insulin
dose (PZ0.11) was controlled.Association of BMI with change in fasting C-peptide
over 1 year (D C-peptide0–1) by age group
At baseline, differences in BMI were not associated with
fasting C-peptide in those diagnosed at %5 years
(PZ0.45). In those diagnosed between 5 and 10 years, a
larger BMI at baseline was significantly associated with
greater fasting C-peptide levels, with each 1 kg/m2 higher
BMI associated with a 4.8% (2.1, 7.5) increase in fasting
C-peptide (PZ0.00052).
BMI was not a predictor of D C-peptide0–1 in those
diagnosed at%5 years (bZ0.003, 95% CIZK0.022, 0.027;
PZ NS) or those diagnosed between 5 and 10 years of age
(bZ0.011, 95% CIZK0.0030, 0.026; PZNS).www.eje-online.org
Table 1 Characteristics of population by age of onset. Data are meanGS.D.
Characteristic Total cohort
Age at diagnosis (years)
%5 O5 and %10 O10 and %18 O18
n (m/f) 1252 (752/500) 126 (79/47) 295 (156/139) 421 (257/164) 410 (260/150)
Age of onset (years) 16.7 (10.6) 3.2 (1.5) 8.2 (1.4) 13.4 (2.1) 29.3 (7.4)
BMI (kg/m2) 18.8 (3.9) 15.3 (2.3) 16.1 (2.7) 18.7 (3.1) 22.0 (3.4)
BMI z-score for age K0.40 (1.3) K1.1 (1.9) K0.26 (1.3) K0.31 (1.1) K0.40 (1.3)
Insulin dose (IU/kg per day) 0.66 (0.37) 0.86 (0.50) 0.70 (0.34) 0.71 (0.35) 0.51 (0.30)
HbA1c (%) 10.3 (3.0) 9.9 (2.4) 9.9 (2.9) 10.0 (3.2) 11.0 (2.8)
Fasting C-peptide (nM) 0.31 (0.37) 0.16 (0.21) 0.21 (0.27) 0.33 (0.40) 0.41 (0.41)
0.00
0.01
0.02
0.03
% 
CI
)
>5 and ≤10
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172 :2 110At baseline, in individuals diagnosed between 10 and
18 years, a higher BMI was associated with higher fasting
C-peptide levels with a 3.3% (0.98, 5.6) increase per
1 kg/m2 difference in BMI (PZ0.0054).
In individuals diagnosed between 10 and 18 years, a
higher BMI at baseline was associated with a greater
decline in fasting C-peptide over 1 year with a decrease
of K0.025 (K0.010, K0.041; 0.001) nM for each 1 kg/m2
higher baseline BMI. This association remained significant
even after differences in baseline HbA1c, and insulin dose
were taken into account (bZK0.026, 95% CIZK0.0097,
K0.042; PZ0.002). Data on BMI 1 year after the diagnosis
were available for 264 subjects. In these subjects, the
association between baseline BMI and the decline in
C-peptide remained significant also after adjustment for
D BMI0–1 (bZK0.028, 95% CIZK0.0049, K0.006;
PZ0.012). The detrimental effect of increased BMI at
baseline was reduced in those individuals with a larger
baseline insulin dose (pinteractionZ0.004).
In individuals diagnosed at O18 years, each 1 kg/m2
higher BMI was associated with a 5.4% (3.3, 7.4) increase
in fasting C-peptide (PZ5.0!10K7); however, baseline
BMI was not a significant predictor of D C-peptide0–1.
The association between changes in BMI and D
C-peptide0–1 in different age of onset groups is shown in
Fig. 1.
Inclusion of BMI z-scores in regression models of
individuals diagnosed at !18 years of age (in place of
untransformed BMI) did not alter the results.–0.05
–0.04
–0.03
–0.02
–0.01
Age of onset group (years)
β 
(95
≤5
>10 and ≤18
>18
Figure 1
Association between 1 kg/m2 change in BMI and D C-peptide0-1
in age of onset and sex-adjusted models by age of onset group.Discussion
This study demonstrates that increased BMI is associated
with an accelerated rate of fasting C-peptide decline over
1 year in newly diagnosed type 1 diabetes patients aged
10–18 years. It is assumed that insulin resistance may play
a role in the pathophysiology or progression to type 1
diabetes, and the results reported here suggest that, inwww.eje-online.orgthose diagnosed with an age of onset of between 10 and 18
years, decreased insulin sensitivity may play an important
role for residual C-peptide after diagnosis.
Although increasing insulin secretion strives to
maintain normal glucose tolerance in response to
reductions in insulin sensitivity, the increased secretory
demand in insulin resistant states can potentially be
detrimental to b-cell function, possibly due to b-cell
dysfunction resulting from the excessive stimulation of
b-cells necessary for the maintenance of normoglycaemia
in insulin-resistant states (24, 25, 26).
It is well known that a greater BMI is associated with
reduction in insulin sensitivity (26, 27), and hence the
greater rate of decline of C-peptide in patients with a
higher BMI could plausibly result from b-cell exhaustion
by the mechanism described previously.
An important question to be addressed is why the
detrimental association of BMI with fasting C-peptide
decline is observed only in those individuals aged 10–18
years. A likely explanation is the pubertal transition that
occurs during this age range. A previous longitudinal
study has shown that during puberty there is a transient
decrease in insulin sensitivity, and hence the pubertal
transition is an example of an insulin-resistant state (28).
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172 :2 111The lack of association between BMI and fasting
C-peptide decline over 1 year in younger and older age
groups may be due to the fact that b-cell dysfunction is
much more severe in the former and much less severe in
the latter (29, 30, 31, 32, 33). Indeed individuals in our
study diagnosed at R18 years of age were not obese
according to typical BMI cut-offs.
The greater decline in C-peptide observed in patients
with a higher BMI could also reflect greater low-grade
inflammation associated with obesity (34, 35).
In the SEARCH for Diabetes in Youth study, the decline
in b-cell function 12 months after the diagnosis was
independent of BMI z-score and insulin resistance among
autoantibodies-positive patients with diabetes diagnosed
at the age of 10–20 years (36). Different to our data, the
SEARCH study used a pathogenesis-based approach for
the classification of diabetes; furthermore, the SEARCH
study included a wide range of racial and ethnic groups
and 23% of the population was not Non-Hispanic White.
Our work may have relevant clinical implications.
Although we are not able to define whether insulin
resistance or adiposity is the main determinant of the
b-cell decline during the first year after diagnosis, the
results presented here may suggest that, especially in
individuals diagnosed between 10 and 18 years of age,
intervention to reduce insulin resistance (e.g. weight loss)
or drugs aimed at improving insulin sensitivity may be
a possible component of therapy aimed at preventing
fasting C-peptide decline, at least in adolescents. In
addition, if the association between BMI and increased
C-peptide decline is a result of pro-inflammatory processes
associated with obesity, then treatments aimed to reduced
inflammation would also be beneficial. Previous studies
have shown that with increasing body weight, systemic
immune mediators increase not only for type 2 diabetes
but also for type 1 diabetes (37, 38). Although anti-IL1
therapy was not effective in a post hoc subanalysis of high
BMI subjects (39), properly powered and designed studies
also testing other anti-inflammatory interventions are
needed to determine this question.
Limitations of our study include the reporting of
results using untransformed BMI variables for the ease of
interpretation and comparison with the data from adults
in our cohorts. To overcome this problem, we repeated
all analyses with BMI z-score variables and found no
difference in results indicating that increased adiposity
is likely to underlie this association.
We have used BMI as a proxy for insulin resistance in
this study, and although the two variables are strongly
related, it would have been preferable to have performedthe analysis by directly measuring insulin resistance;
however, direct measurement of insulin resistance was
not available for analysis. We quantified b-cell function
by analysing C-peptide in the fasting state, which may
only partially reflect b-cell function in the stimulated state
(e.g. after a meal). Although we did have data on
stimulated C-peptide, a limited number of patients had
sufficient data for analysis; hence we decided to maximise
our sample size by using fasting C-peptide alone as our
outcome variable. Data are also limited by the use of
different C-peptide assays though all assays had similar
detection limits.
Moreover, we did not adjust linear regression models
for baseline C-peptide. However, the inclusion of fasting
C-peptide at baseline in models is actually a matter of
debate in statistical analysis. Thus, we decided not to
include it as it may introduce a bias (40).
Another limitation is that diabetes-associated auto-
immunity was not evaluated in our study and this
parameter appears to be a major variable associated with
b-cell decline, at least in patients !20 years of age at
diagnosis (36).
In conclusion, our work provides supportive evidence
for a key role of body mass in type 1 diabetes disease
progression after diagnosis. However, additional studies
are needed to define whether insulin resistance or
adiposity are key factors leading to b-cell decline soon
after diagnosis of type 1 diabetes.Declaration of interest
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